{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T19:18:27Z","timestamp":1769455107462,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"North-Eastern German Society of Gynecological Oncology (NOGGO)"},{"DOI":"10.13039\/501100014841","name":"MEDAC GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00432-016-2307-0","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T09:32:43Z","timestamp":1480325563000},"page":"541-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)"],"prefix":"10.1007","volume":"143","author":[{"given":"Jalid","family":"Sehouli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Tom\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desislava","family":"Dimitrova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumar","family":"Camara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo Bernhard","family":"Runnebaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Werner","family":"Tessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Rautenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radoslav","family":"Chekerov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Zelal","family":"Muallem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Patrick","family":"Lux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Trarbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Gitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"2307_CR1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20132045. doi: 10.1200\/JCO.2012.42.0505","journal-title":"J Clin Oncol"},{"key":"2307_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2196-8","author":"H Boztug","year":"2014","unstructured":"Boztug H, Zecca M, Sykora K-W, Veys P, Lankester A, Slatter M et al (2014) Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol. doi: 10.1007\/s00277-014-2196-8","journal-title":"Ann Hematol"},{"issue":"1","key":"2307_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","volume":"15","author":"R Angelis de","year":"2014","unstructured":"de Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R, EUROCARE-5 Working Group (2014) Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE\u20135-a population-based study. Lancet Oncol 15(1):23\u201334. doi: 10.1016\/S1470-2045(13)70546-1","journal-title":"Lancet Oncol"},{"key":"2307_CR4","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374\u20131403. doi: 10.1016\/j.ejca.2012.12.027","journal-title":"Eur J Cancer"},{"key":"2307_CR5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1006\/gyno.1998.5103","volume":"71","author":"M Gropp","year":"1998","unstructured":"Gropp M, Meier W, Hepp H (1998) Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 71:94\u201398. doi: 10.1006\/gyno.1998.5103","journal-title":"Gynecol Oncol"},{"issue":"10","key":"2307_CR6","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E et al (2012) The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann Oncol 23(10):2605\u20132612. doi: 10.1093\/annonc\/mds203","journal-title":"Ann Oncol"},{"key":"2307_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s002800051023","volume":"45","author":"RA Hilger","year":"2000","unstructured":"Hilger RA, Jacek G, Oberhoff C, Kredtke S, Baumgart J, Seeber S et al (2000) Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol 45:483\u2013488. doi: 10.1007\/s002800051023","journal-title":"Cancer Chemother Pharmacol"},{"key":"2307_CR8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/gyno.1998.4984","volume":"69","author":"N Keldsen","year":"1998","unstructured":"Keldsen N, Madsen EL, Havsteen H, Kamby C, Laursen L, Sandberg E (1998) Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish ovarian cancer study group. Gynecol Oncol 69:100\u2013102","journal-title":"Gynecol Oncol"},{"key":"2307_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00688319","volume":"37","author":"P K\u00f6pf-Maier","year":"1996","unstructured":"K\u00f6pf-Maier P, Sass G (1996) Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol 37:211\u2013221","journal-title":"Cancer Chemother Pharmacol"},{"key":"2307_CR10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. JCO 15:110\u2013115","journal-title":"JCO"},{"key":"2307_CR11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00432-012-1221-3","volume":"138","author":"S Mahner","year":"2012","unstructured":"Mahner S, Oskay-\u00d6zcelik G, Heidrich-Lorsbach E, Fuxius S, Sommer H, Klare P et al (2012) A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. J Cancer Res Clin Oncol 138:1413\u20131419. doi: 10.1007\/s00432-012-1221-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"2307_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1\u20136. doi: 10.1056\/NEJM199601043340101","journal-title":"N Engl J Med"},{"key":"2307_CR13","first-page":"2221","volume":"17","author":"H Meden","year":"1997","unstructured":"Meden H, Wittkop Y, Kuhn W (1997) Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity. Anticancer Res 17:2221\u20132223","journal-title":"Anticancer Res"},{"key":"2307_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2009.04.026","volume":"114","author":"W Meier","year":"2009","unstructured":"Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M et al (2009) Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12\u00a0months following 1st-line platinum\/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 114:199\u2013205. doi: 10.1016\/j.ygyno.2009.04.026","journal-title":"Gynecol Oncol"},{"key":"2307_CR15","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","volume":"28","author":"BJ Monk","year":"2010","unstructured":"Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM et al (2010) Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 28:3107\u20133114. doi: 10.1200\/JCO.2009.25.4037","journal-title":"J Clin Oncol"},{"key":"2307_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RHJ, Sonke GS et al (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16:87\u201397. doi: 10.1016\/S1470-2045(14)71135-0","journal-title":"Lancet Oncol"},{"issue":"20","key":"2307_CR17","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20):3323\u20133329. doi: 10.1200\/JCO.2009.25.7519","journal-title":"J Clin Oncol"},{"issue":"13","key":"2307_CR18","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302\u20131308. doi: 10.1200\/JCO.2013.51.4489","journal-title":"J Clin Oncol"},{"issue":"2","key":"2307_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2005.09.022","volume":"42","author":"NS Reed","year":"2006","unstructured":"Reed NS, Poole CJ, Coleman R, Parkin D, Graham JD, Kaye SB et al (2006) A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG). Eur J Cancer 42(2):179\u2013185. doi: 10.1016\/j.ejca.2005.09.022","journal-title":"Eur J Cancer"},{"issue":"19","key":"2307_CR20","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","volume":"26","author":"J Sehouli","year":"2008","unstructured":"Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P et al (2008) Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26(19):3176\u20133182. doi: 10.1200\/JCO.2007.15.1258","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-016-2307-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-016-2307-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T10:28:48Z","timestamp":1589711328000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-016-2307-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["2307"],"URL":"https:\/\/doi.org\/10.1007\/s00432-016-2307-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]}}}